202 related articles for article (PubMed ID: 32684628)
1. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
[TBL] [Abstract][Full Text] [Related]
2. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
3. Primary Cutaneous Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring RANBP2-ALK Fusion: Report of an Exceptional Case.
Gadeyne L; Creytens D; Dekeyser S; Van der Meulen J; Haspeslagh M
Am J Dermatopathol; 2022 Apr; 44(4):302-305. PubMed ID: 34816804
[TBL] [Abstract][Full Text] [Related]
4. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
5. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
6. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
7. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature.
Yu L; Liu J; Lao IW; Luo Z; Wang J
Diagn Pathol; 2016 Jul; 11(1):67. PubMed ID: 27460384
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib in ALK
Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
[TBL] [Abstract][Full Text] [Related]
9. Epithelioid inflammatory myofibroblastic sarcoma: a pitfall in the differential diagnosis of ALK-positive anaplastic large cell lymphoma.
Fadl A; Feldman AL
J Hematop; 2023 Jun; 16(2):125-126. PubMed ID: 37398940
[TBL] [Abstract][Full Text] [Related]
10. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
11. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.
Lee JC; Li CF; Huang HY; Zhu MJ; Mariño-Enríquez A; Lee CT; Ou WB; Hornick JL; Fletcher JA
J Pathol; 2017 Feb; 241(3):316-323. PubMed ID: 27874193
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
14. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
15. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
16. Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.
Jiang Q; Tong HX; Hou YY; Zhang Y; Li JL; Zhou YH; Xu J; Wang JY; Lu WQ
Orphanet J Rare Dis; 2017 May; 12(1):97. PubMed ID: 28535796
[TBL] [Abstract][Full Text] [Related]
17. CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice.
Matsuhashi M; Nishida K; Sakamoto M; Gion Y; Yoshida A; Katsuyama T; Nakahara R; Nasu Y; Matsumoto Y; Sato Y; Ozaki T
Inflamm Res; 2022 Feb; 71(2):215-226. PubMed ID: 35064306
[TBL] [Abstract][Full Text] [Related]
18. A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.
Wei W; Lin Y; Song Z; Xiao W; Chen L; Yin J; Zhou Y; Barta SK; Petrus M; Waldmann TA; Yang Y
Clin Cancer Res; 2020 Aug; 26(15):4093-4106. PubMed ID: 32299816
[TBL] [Abstract][Full Text] [Related]
19. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
[TBL] [Abstract][Full Text] [Related]
20. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]